{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:32:54Z","timestamp":1783488774302,"version":"3.55.0"},"reference-count":20,"publisher":"The Endocrine Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>Conventional therapy for hypoparathyroidism consists of calcium and calcitriol, but sometimes normal serum calcium cannot be maintained, and\/or this approach might lead to nephrocalcinosis, nephrolithiasis, or renal insufficiency.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>The objective of the study was to investigate the effects of 6 months of PTH(1\u201334) treatment in adult subjects with postoperative hypoparathyroidism and to evaluate quality-of-life changes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design:<\/jats:title>\n                  <jats:p>This was a 2-year prospective, open-label study. At baseline and after 6 months of PTH(1\u201334) treatment, calcium and vitamin D supplementation requirements, serum calcium, phosphate, creatinine, alkaline phosphatase, uric acid, and 24-hour urinary calcium excretion were evaluated. Quality of life was evaluated by the Rand 36-Item Short Form Health Survey covering eight domains of physical and mental health.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting:<\/jats:title>\n                  <jats:p>This was an Italian multicentric study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants:<\/jats:title>\n                  <jats:p>Participants included 42 subjects with surgical hypoparathyroidism (90% females, age range 34\u201377 y).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention:<\/jats:title>\n                  <jats:p>The intervention included a twice-daily PTH(1\u201334) 20 \u03bcg sc injection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>The mean serum calcium levels significantly increased from baseline to 15 days (7.6 \u00b1 0.6 vs 9.1 \u00b1 0.9 mg\/dL, P &amp;lt; .001) and remained stable until the end of the observational period, despite a significant reduction in calcium and vitamin D supplementation. Phosphate levels gradually decreased from baseline to the sixth month (P = .005 for the trend), whereas the alkaline phosphatase increased (P &amp;lt; .001). Data from the Rand 36-Item Short Form Health Survey showed a significant improvement in the mean scores of all eight domains (P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>This is the largest study that demonstrates the effectiveness of PTH(1\u201334) in the treatment of adult patients with postsurgical hypoparathyroidism, and it shows that PTH(1\u201334) may improve the mental and physical health in hypoparathyroid subjects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2015-1855","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T17:02:38Z","timestamp":1437498158000},"page":"3590-3597","source":"Crossref","is-referenced-by-count":56,"title":["PTH(1\u201334) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life"],"prefix":"10.1210","volume":"100","author":[{"given":"Assunta","family":"Santonati","sequence":"first","affiliation":[{"name":"Department of Endocrinology (A.Sa., D.B., A.Sp.), San Giovanni Addolorata Hospital, 00184 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes (A.P., E.M., S.M.), University Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Maddaloni","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes (A.P., E.M., S.M.), University Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bosco","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (A.Sa., D.B., A.Sp.), San Giovanni Addolorata Hospital, 00184 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (A.Sa., D.B., A.Sp.), San Giovanni Addolorata Hospital, 00184 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes (F.G., F.V.), Santa Maria della Misericordia Hospital, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Raggiunti","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (B.R.), Hospital San Liberatore Atri, 64032 Teramo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Volpe","sequence":"additional","affiliation":[{"name":"Department of Endocrinology (R.V.), Cardarelli Hospital, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Manfrini","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes (A.P., E.M., S.M.), University Campus Bio-Medico, 00128 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vescini","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes (F.G., F.V.), Santa Maria della Misericordia Hospital, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Hypoparathyroidism AME Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616435888700_B1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/B:REMD.0000016123.21743.fe","article-title":"Genetics of endocrine and metabolic disorders: parathyroid","volume":"5","author":"Thakker","year":"2004","journal-title":"Rev Endocr Metab Disord"},{"key":"2020071616435888700_B2","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020071616435888700_B3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"2020071616435888700_B4","first-page":"141","article-title":"First experiences in the substitution treatment of hypoparathyroidism with synthetic human parathyroid hormone","volume":"138","author":"Str\u00f6gmann","year":"1990","journal-title":"Monatsschr Kinderheilkd"},{"key":"2020071616435888700_B5","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int"},{"key":"2020071616435888700_B6","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1210\/jc.2013-1239","article-title":"The effect of PTH(1\u201384) on quality of life in hypoparathyroidism","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616435888700_B7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1\u201384): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616435888700_B8","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020071616435888700_B9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"key":"2020071616435888700_B10","first-page":"391","article-title":"Synthetic human parathyroid hormone 1\u201334 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616435888700_B11","first-page":"3480","article-title":"A randomized, crossover trial of once-daily vs twice-daily human parathyroid hormone 1\u201334 in the treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616435888700_B12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1\u201334 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"2020071616435888700_B13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00198-012-2230-4","article-title":"PTH replacement therapy of hypoparathyroidism","volume":"24","author":"Rejnmark","year":"2013","journal-title":"Osteoporos Int"},{"key":"2020071616435888700_B14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.ejcn.1601278","article-title":"Validation of a food frequency questionnaire for nutritional calcium intake assessment in Italianwomen","volume":"56","author":"Montomoli","year":"2002","journal-title":"Eur J Clin Nutr"},{"key":"2020071616435888700_B15","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1210\/jc.2014-2267","article-title":"PTH(1\u201384) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy","volume":"99","author":"Cusano","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616435888700_B16","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1\u201384) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020071616435888700_B17","first-page":"801","article-title":"Catabolic and anabolic actions of parathyroid hormone on the skeleton","volume":"34","author":"Silva","year":"2011","journal-title":"J Endocrinol Invest"},{"key":"2020071616435888700_B18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1210\/jc.2009-2682","article-title":"Parathyroid hormone stimulates circulating osteogenic cells in hypoparathyroidism","volume":"96","author":"Rubin","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616435888700_B19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11914-008-0003-y","article-title":"Safety of parathyroid hormone for the treatment of osteoporosis","volume":"6","author":"Miller","year":"2008","journal-title":"Curr Osteoporos Rep"},{"key":"2020071616435888700_B20","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00198-014-2677-6","article-title":"Effects of PTH(1\u201384) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial","volume":"25","author":"Sikjaer","year":"2014","journal-title":"Osteoporos Int"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/9\/3590\/10435859\/jcem3590.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/100\/9\/3590\/10435859\/jcem3590.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:22:35Z","timestamp":1594956155000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/100\/9\/3590\/2830531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,1]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2015-1855","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,1]]}}}